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Objectives: Ethics committees often require cross-over design for highly sen-
sitive circumstances where it may be unethical to withhold active therapy. This 
can be the case particularly in oncology. Cross over can, however, dilute the treat-
ment effect seen in trial analyses. The German Institute for Quality and Efficiency 
in Health Care (IQWiG) follows distinct thresholds for comparative treatment 
effect, which it requires for a positive early benefit assessment (EBA) rating. The 
upper 95% confidence interval must be at least 0.85 to receive the highest rating. 
We evaluated if cross-over designs may negatively affect benefit assessment in 
Germany. MethOds: Oncology medicines that finished EBA procedures in Germany 
until June 2014 were evaluated for cross over in the manufacturer’s dossier. The 
extent of cross over on the observed treatment effects was investigated, as well 
as how the designs may affect the EBA ratings. Results: Ten out of 24 EBAs in 
oncology included assessment of trials with cross-over design. Cross over may have 
affected the observed treatment effects as demonstrated by a number of examples. 
Firstly, the proportion of patient cross over was as high as 62% for crizotinib. For van-
detanib, 12 out of 13 remissions in the control group could be attributed to a switch 
to active therapy. The hazard ratio for overall survival (OS) with vemurafenib versus 
dacarbazine was 0.37 without cross over at first data-cut in comparison to 0.62 with 
24% cross over at a later timepoint. These examples suggest that cross-over designs 
are both present in EBAs in oncology, and may affect the extent of comparative 
treatment effect. The affect of cross-over design was not systematically considered 
by IQWiG. cOnclusiOns: Cross-over design is an ethical necessity. However, it is 
known that these designs dilute treatment effect signals. German HTA EBAs need 
to improve in systematically accounting for such cross-over affects.
PCN249
reimBurseD PharmaCoTheraPy of meTasTaTiC Clear Cell KiDNey 
CaNCer (mCCKC) iN The CzeCh rePuBliC
Mazelova J., Slaby J.
State Institute for Drug Control, Prague, Czech Republic
Objectives: Concise analysis of reimbursement of drugs for mCCKC. Evaluation 
was performed from the aspect of the regulator; it regards drugs approved for use 
in outpatient care. The aim was to identify the development of criteria that must be 
met by reimbursed drugs, with regard to pharmacoeconomics and evidence-based 
medicine data. MethOds: We performed a search of the database of administrative 
proceedings (including proceedings on reimbursement determination as well as on 
reimbursement revisions) and detected those in which the Decision has already 
been made. Subsequently, an analysis of submitted evidence was carried out in 
cases where the reimbursement conditions were first set or amended. Results: 
Between Jan/2008 and Jun/2014, decisions were issued in 25 relevant proceedings 
regarding 9 drugs. Before 2008 (when the pricing and reimbursement decision com-
petence was transferred to the Institute) only interpheron-alpha (IFN) and inter-
leukin-2 (IL2) were reimbursed in this indication. The proceedings carried out by 
the Institute led in IFN and IL2 only to precision of the conditions to better reflect 
real clinical practice (obsolete regimens were left out). In IL2 the reimbursement 
conditions for the 1st line of treatment were extended to include the combination 
with bevacizumab (no pharmacoeconomics required as the evidence had already 
been assessed and relevant conditions approved for bevacizumab). For the other 
medicines, the reimbursement conditions were set or amended based on scientific 
evidence and pharmacoeconomics (1st line: sunitinib ICER/LYG: 25,9 t€ , sorafenib 
ICER/PFLY: 42,8 t€ , bevacizumab: 96,3 t€ ; 1st and 2nd line: pazopanib - CMA analysis 
vs. sunitinib; 2nd line: axitinib ICER/QALY 57,0 t€ , 2nd or 3rd line: everolimus: ICER 
per LYG: 6,9 t€ , ICER; temsirolimus: only costs per LYG: 13,7 t€ ). cOnclusiOns: 
Setting the reimbursement conditions depended not only on the submitted evi-
dence and pharmacoeconomic data but also on other elements (public interest, 
burden of the disease).
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Objectives: To identify differences in the recommendations for targeted cancer 
therapies (TCT) in three distinctive European health care systems: Serbian, Scottish 
and Dutch, and to examine the role of cost effectiveness analyses (CEA) in such 
recommendations. MethOds: A list of currently approved TCTs cited from the 
European Medicines Agency (EMA) was cross-referenced with the drug reimburse-
ment reports issued by Health Insurance Fund (RFZO) for Serbia, Scottish Medicines 
Consortium (SMC) for Scotland and Health Institute (ZI) for the Netherlands. The 
following key variables were gathered from the reports: drug indication, registra-
tion status, reimbursement status and outcome of the cost effectiveness evalu-
ation. Results: There were 44 TCTs indicated for 75 cancer sites and approved 
by EMA. Out of total number of drugs per indication (d/i= 75), 20 were reimbursed 
in Serbia, and 15 are still without the decision from RFZO. Remaining majority of 
TCTs is not registered in Serbia. None of submissions neither CEAs were publically 
available. SMC positively assessed 25 d/i and rejected as much as 30. All apprais-
als were published, and majority contained full CEAs. Finally, Dutch ZI accepted 
total of 59 d/i and disapproved use of only 5 d/i. The majority of reimbursed drugs 
were exempted from CEA in accordance with the policy for expensive hospital 
drugs. cOnclusiOns: Although data collected for Serbia did not allow us to evalu-
ate practiced policy in broader extent, it is certainly surrounding with the smallest 
number of reimbursed TCTs. Surprisingly, TCTs in Scotland were comparable to 
this number, yet reasons for such an outcome were fairly different. It seems that 
full application of CEA in TCTs submission contributed to 55% of SMC negative 
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Objectives: FN is a cost-intensive complication of chemotherapy. The study aimed to 
describe HCRU in hospitalized FN patients in BG, CZ and SK. MethOds: Multicentre 
international, retrospective, observational study in adult patients, who received the 
chemotherapy leading to the first (= index) FN event between 01/2009 and 09/2012. 
FN-specific HCRU parameters included infection prophylaxis and treatments, G-CSF 
use, other prophylactic medication, specific interventions and investigations, and 
FN-related hospitalizations. Unless otherwise stated, country data are reported in 
the order BG–CZ–SK. Results: 314 patients (156, 79, 79) with a median age of 55.5, 
56.0, and 57.0 years, and mostly ECOG status 0-2 (81%, 100%, 91%) were analysed. Most 
frequent STs and HMs were breast cancer (23% BG; 24% SK), testicular cancer (28% CZ); 
acute myeloid leukemia (29% BG), non-follicular lymphoma (31% CZ; 33% SK). G-CSF 
was used in the index cycle by 92%, 91%, and 68% of patients, usually as treatment 
(64%, 27%, 57%) rather than primary prophylaxis (20%, 41%, 8%). Most patients had one 
FN episode (88%, 96%, 94%), mostly in cycle 1 (56%; 72%; 58%). The mean (SD) number 
of FN-related hospital days was 7.2 (4.78), 7.2 (6.04), and 9.2 (5.12), with generally 
longer stays in HM than ST patients. The number of FN-related investigations in the 
index cycle were 531 in 125 patients (80%), 496 (49; 62%), and 585 (66; 84%); FN-related 
interventions: 416 (109; 70%), 328 (46; 58%), and 473 (55; 70%), respectively. The most 
frequent investigations were blood tests; the most frequent interventions were IV 
fluids and blood transfusions. Anti-infectives were frequently administered in the 
index cycle (72%, 98%, 99%). G-CSF use, FN-related investigations, interventions and 
anti-infective use continued in subsequent cycles. cOnclusiOns: Results indicate 
considerable HCRU in patients experiencing FN in all countries. Frequent lack of G-CSF 
primary prophylaxis was observed, particularly in SK.
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bAckgROund: Finland has more favourable profile in breast cancer statistics 
compared to Hungary, along with an almost double participation rate in screening 
examinations. However, regarding medical practice and access to latest treatment 
only minor differences exist. Main hypothesis of the research was that awareness, 
knowledge and therefore better attitude towards breast cancer screening explains 
the difference in primary prevention’s efficiency. Objectives: The aim of the ques-
tionnaire survey was to assess what extent women are aware of the prevention 
opportunities in their home country as well as being aware of risk factors of breast 
cancer; furthermore what impact does it have on their behaviour how they assess 
their own general health status and risk of cancer. MethOds: A web-based ques-
tionnaire survey was carried out in 2013-2014 among adult women. Demographic 
characteristics, lifestyle, general and cancer-specific health status (including per-
sonal and family history of breast cancer), knowledge and experience with primary 
prevention were covered. An internationally utilized medical risk calculator was 
included in the questionnaire for classifying responders based on their calculated 
risk of breast cancer, as well as to compare those to the risk assumed by them-
selves. Results: More than 400 participants were involved in the survey from the 
two countries. There were no significant differences identified in the acknowledged 
personal and family health background. Main difference was in the participation 
inclination in screening. Source of getting information means a major impact on 
prevention-related behaviour. Formal education and informing by medical staff 
were the most effective, however magnitude of uncontrolled ‘self-education’ via 
internet and social media is increasing with a potential biasing impact on knowl-
edge. cOnclusiOns: Survey results suggest that utilizing participation ratio in 
comparative screening assessment as a key parameter. Results indicate that partici-
pation can be influenced by increasing efficiency of information flow, with proper 
education as one of the main intervention opportunities.
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Objectives: With the introduction of new pricing measures in countries such as 
Germany, the visibility of net pharmaceutical product prices (prices with a manda-
tory rebate) could soon become a requirement. Three European markets that cur-
rently employ rebates are Germany, Spain and Italy. The objective of this study is 
to map out likely consequences of International Price Referencing (IRP) using net 
prices on three products; Avastin, Caprelsa and Vidaza. MethOds: Using data from 
PRICENTRIC, we collected net and list ex-factory prices for Avastin, Caprelsa and 
Vidaza across EU-28. Countries that do not use formal IRP as a price setting mecha-
nism were excluded from the analysis, countries that consider price reviews were 
included. Projected prices were calculated using country IRP rules and exchange 
rates from the European Central Bank. The current approved prices were compared 
to the likely projected prices. The analysis investigated two key areas: 1. Countries 
impacted 2. Potential price impact. Results: Figure 1 shows the current prices for 
the 3 products. Figure 2 illustrates the countries impacted by the change and likely 
price points. One of the first countries affected would be Netherlands (Netherlands 
reviews prices every 6 months), followed closely by Switzerland and Ireland. The 
potential impact could range from price reductions of 9.69% for Vidaza in Ireland to 
30.77% for Avastin in Switzerland. cOnclusiOns: The trend for net price referenc-
ing has already been adopted by Greece since February 2014 where Greece moved 
from referencing the Italian list price to the net price. The concern for industry if 
this were to become the norm for other markets and if net prices were to become 
publically visible, substantial price reductions could be on the horizon.
